Allogene Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDAllogene Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings growth of 39% provides fundamental context to the price action. Investors should exercise caution due to high volatility (92% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.33 | -2.62% | BELOW |
| 50 SMA | $2.41 | -5.80% | BELOW |
| 100 SMA | $2.03 | +11.71% | ABOVE |
| 150 SMA | $1.79 | +27.09% | ABOVE |
| 200 SMA | $1.63 | +38.92% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ALLO in an uptrend right now?
ALLO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ALLO overbought or oversold?
ALLO's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is ALLO outperforming the market?
ALLO has a Relative Strength (RS) Rating of 85 out of 99. Yes, ALLO is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is ALLO in its 52-week range?
ALLO is trading at $2.27, which is 51% of its 52-week high ($4.46) and 39% above its 52-week low ($0.86).
How volatile is ALLO?
ALLO has a Beta of 2.58 and 52-week volatility of 92%. It's more volatile than the S&P 500 - expect bigger swings.